Fiona Miall

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Kirit M. Ardeshna, Wendi Qian, Paul Smith et al. · The Lancet Oncology · 2014 · 388 citations

Medicine, Oncology, Pharmacotherapy +8

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

Kirit M. Ardeshna, Wendi Qian, Paul Smith et al. · Blood · 2010 · 104 citations

Medicine, Immunology, Oncology +6

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Nicole Wong Doo, Carole Soussain, Sylvain Choquet et al. · UCL Discovery (University College London) · 2022 · 76 citations

Medicine, Pharmacology, Pharmacotherapy +10

Enhancement of <scp>CD</scp>154/<scp>IL</scp>4 proliferation by the <scp>T</scp> follicular helper (<scp>T</scp>fh) cytokine, <scp>IL</scp>21 and increased numbers of circulating cells resembling <scp>T</scp>fh cells in chronic lymphocytic leukaemia

Matthew J. Ahearne, Shaun Willimott, Lucia Piñon et al. · British Journal of Haematology · 2013 · 69 citations · Full text

Life Sciences, Hematology, Immunology +17

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL

Aneela Majid, Thet Thet Lin, Giles Best et al. · Leukemia Research · 2010 · 63 citations

Life Sciences, Cell Biology, Immunology +8